GSK's VC unit SR One has new chief

There's some new blood at the helm of London-based drug giant GlaxoSmithKline's venture group. Jens Eckstein, previously a venture partner and entrepreneur-in-residence at TVM Capital, has jumped aboard as president of SR One. He takes over for biotech venture capitalist Christoph Westphal, who had been wearing multiple hats. Westphal ran the show at SR One while serving as a partner of his own VC group, Longwood Founders Fund, which has funding support from GSK, Genzyme and other sources. Eckstein, a biochemist by training, was a general partner focused on early stage life sciences investments before his role changed to venture partner and EIR earlier this year. Release

Suggested Articles

Despite the setback, Fulcrum hailed the data as “very encouraging,” zeroing in on results from a pre-specified sensitivity analysis to make its case.

Bayer has struck a $425 million upfront deal to buy KaNDy in the belief its treatment for menopause-related hot flashes has blockbuster potential.

After its recent $4.8 billion buyout of gene therapy specialist Spark Therapeutics, Roche is now handing over one of its execs as its CMO.